Anti-CARM1 antibody
Specifications
| Product type: | Primary antibody |
| Antigen: | CARM1 |
| Immunogen: | Purified recombinant fragment of human PRMT4 expressed in E. Coli. |
| Species immunized: | Mouse |
| Isotype: | IgG1 |
| Applications: | Western Blot (1:400-1:1000); Immunohistochemistry (1:100-1:400); Immunocytochemistry (1:100-1:400); Flow Cytometry (1:50-1:200) |
| Reactivity: | Human, Mouse, Rat, Monkey |
| Clonality (clone number): | Monoclonal, B10-H2 |
| Form: | Liquid |
| Buffer: | Tris-HCl buffer (pH7.4), 1% BSA, 0.05% NaN3 and 50% Glycerol. |
| Concentration: | 1mg/ml |
| Purity: | Protein A/G affinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | Carm1 antibody |
| CARM1_HUMAN antibody | |
| Coactivator associated arginine methyltransferase 1 antibody | |
| Coactivator-associated arginine methyltransferase 1 antibody | |
| Histone arginine methyltransferase CARM 1 antibody | |
| Histone arginine methyltransferase CARM1 antibody | |
| Histone-arginine methyltransferase CARM1 antibody | |
| PRMT 4 antibody | |
| PRMT4 antibody | |
| Protein arginine methyltransferase antibody | |
| Protein arginine N methyltransferase 4 antibody | |
| Protein arginine N-methyltransferase 4 antibody |
Target information
Methylates (mono- and asymmetric dimethylation) the guanidino nitrogens of arginyl residues in several proteins involved in DNA packaging, transcription regulation, pre-mRNA splicing, and mRNA stability. Recruited to promoters upon gene activation together with histone acetyltransferases from EP300/P300 and p160 families, methylates histone H3 at ‘Arg-17’ (H3R17me), forming mainly asymmetric dimethylarginine (H3R17me2a), leading to activate transcription via chromatin remodeling. During nuclear hormone receptor activation and TCF7L2/TCF4 activation, acts synergically with EP300/P300 and either one of the p160 histone acetyltransferases NCOA1/SRC1, NCOA2/GRIP1 and NCOA3/ACTR or CTNNB1/beta-catenin to activate transcription. During myogenic transcriptional activation, acts together with NCOA3/ACTR as a coactivator for MEF2C. During monocyte inflammatory stimulation, acts together with EP300/P300 as a coactivator for NF-kappa-B. Acts as coactivator for PPARG, promotes adipocyte differentiation and the accumulation of brown fat tissue. Plays a role in the regulation of pre-mRNA alternative splicing by methylation of splicing factors. Also seems to be involved in p53/TP53 transcriptional activation. Methylates EP300/P300, both at ‘Arg-2142’, which may loosen its interaction with NCOA2/GRIP1, and at ‘Arg-580’ and ‘Arg-604’ in the KIX domain, which impairs its interaction with CREB and inhibits CREB-dependent transcriptional activation. Also methylates arginine residues in RNA-binding proteins PABPC1, ELAVL1 and ELAV4, which may affect their mRNA-stabilizing properties and the half-life of their target mRNAs.
Provider
Erpantech Laboratory
